Nearly $650k awarded to advance potential remyelination drug IFB-048
The National Multiple Sclerosis Society has awarded Inflectis BioScience a grant valued at $649,601 to advance the preclinical development of IFB-048, the company’s experimental treatment to promote myelin repair in multiple sclerosis (MS). “This grant along with the support from the Society are a testimony…